AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates

By Zacks7 days ago

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.30 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 7.04%. A quarter ago, it was expected that this company would post earnings of $1.94 per share when it actually produced earnings of $1.20, delivering a surprise of -38.14%.


Over the last four quarters, the company has surpassed consensus EPS estimates just once.

AnaptysBio, Inc.Which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $11.25 million for the quarter ended March 2021, missing the Zacks Consensus Estimate by 1.45%. This compares to year-ago revenues of $15 million. The company has not been able to beat consensus revenue estimates over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Continue read on